Idecabtagene vicleucel significantly extended PFS compared with standard regimens for adults with triple-class refractory multiple myeloma, results of the randomized phase 3 KarMMa-3 trial showed.
A single-infusion of the modified cellular therapy also induced a significantly higher response rate than standard regimens, according to data presented at European Society for Blood and Marrow Transplantation-European Hematology Association (EHA) 5th European CAR T-cell Meeting and published in The New England Journal of Medicine.
The findings correspond to a 51% reduction in risk for disease
